Proinsulin/insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity

Diabetes Care

Volumn 36, Issue 8, 2013, Pages 2266-2270

  Yu, Liping ^a   Dong, Fran ^a   Miao, Dongmei ^a   Fouts, Alexandra R ^a   Wenzlau, Janet M ^a   Steck, Andrea K ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE 65; INSULIN; PROINSULIN; UNCLASSIFIED DRUG; ZINC TRANSPORTER; ZINC TRANSPORTER 8; CATION TRANSPORT PROTEIN; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2; INSULIN ANTIBODY; SLC30A8 PROTEIN, HUMAN;

ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; CHEMOLUMINESCENCE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FIRST DEGREE RELATIVE; GENETIC RISK; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PROSPECTIVE STUDY; BLOOD; EVALUATION STUDY; IMMUNOLOGY; INFANT; LUMINESCENCE; PANCREAS ISLET; PREDIABETIC STATE; PRESCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

AUTOANTIBODIES; CATION TRANSPORT PROTEINS; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; GLUTAMATE DECARBOXYLASE; HUMANS; INFANT; INSULIN ANTIBODIES; ISLETS OF LANGERHANS; LUMINESCENT MEASUREMENTS; PREDIABETIC STATE; PROINSULIN; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84886055195     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2245     Document Type: Article

References (23)

1. Yu L, Cuthbertson DD, Maclaren N, et al. Expression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplasmic ICA+ relatives is associated with eligibility for the Diabetes Prevention Trial-Type 1. Diabetes 2001;50:1735-1740
2. Orban T, Sosenko JM, Cuthbertson D, et al.; Diabetes Prevention Trial-Type 1 Study Group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009;32:2269-2274
3. Siljander HT, Simell S, Hekkala A, et al. Predictive characteristics of diabetes associated autoantibodies among children with HLA-conferred disease susceptibility in the general population. Diabetes 2009; 58:2835-2842
4. Bingley PJ, Gale EA. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic andmetabolic markers of risk. Diabetol 2006;49:881-890
5. GreenbaumCJ, Palmer JP,Kuglin B, Kolb H. Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement. J Clin Endocrinol Metab 1992;74: 1040-1044
6. Baekkeskov S, Aanstoot H-J, Christgau S, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA synthesizing enzyme glutamic acid decarboxylase. Nature 1990;347:151-156 [published erratum appears in Nature 1990;347(6295):782]
7. Gianani R, Rabin DU, Verge CF, et al. ICA512 autoantibody radioassay. Diabetes 1995;44:1340-1344
8. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007;104: 17040-17045
9. Verge CF, Gianani R, Kawasaki E, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun 1996;9: 379-383
10. Steck AK, Johnson K, Barriga KJ, et al. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diabetes Care 2011; 34:1397-1399
11. Vardi P, Ziegler AG, Mathews JH, et al. Concentration of insulin autoantibodies at onset of type I diabetes. Inverse loglinear correlation with age. Diabetes Care 1988;11:736-739
12. Yu L, Miao D, Scrimgeour L, Johnson K, Rewers M, Eisenbarth GS. Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes 2012;61:179-186
13. Wenzlau JM, Moua O, Sarkar SA, et al. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann N Y Acad Sci 2008;1150:256-259
14. Siljander HT, Veijola R, Reunanen A, Virtanen SM, Akerblom HK, Knip M. Prediction of type 1 diabetes among siblings of affected children and in the general population. Diabetol 2007;50:2272-2275
15. Knip M, Korhonen S, Kulmala P, et al. Prediction of type 1 diabetes in the general population. Diabetes Care 2010;33:1206-1212
16. Sosenko JM, Skyler JS, Mahon J, et al.; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group. The application of the diabetes prevention trialtype 1 risk score for identifying a preclinical state of type 1 diabetes.DiabetesCare 2012; 35:1552-1555
17. NakayamaM, Abiru N, Moriyama H, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005;435:220-223
18. Babaya N, Nakayama M, Moriyama H, et al. A new model of insulin-deficient diabetes: male NOD mice with a single copy of Ins1 and no Ins2. Diabetol 2006; 49:1222-1228
19. Nakayama M, Babaya N, Miao D, et al. Long-term prevention of diabetes and marked suppression of insulin autoantibodies and insulitis in mice lacking native insulin B9-23 sequence. Ann N Y Acad Sci 2006;1079:122-129
20. Kash SF, Condie BG, Baekkeskov S. Glutamate decarboxylase and GABA in pancreatic islets: lessons from knock-out mice. Horm Metab Res 1999;31:340-344
21. Kubosaki A, Miura J, Notkins AL. IA-2 is not required for the development of diabetes in NOD mice. Diabetol 2004;47: 149-150
22. Hu CY, Rodriguez-Pinto D, Du W, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007;117: 3857-3867
23. Pescovitz MD, Greenbaum CJ, Krause- SteinraufH, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361: 2143-2152